Shopping Cart
Remove All
Your shopping cart is currently empty
TBK1/IKKε-IN-4, a 6-aminopyrazolopyrimidine derivative, serves as a potent, selective inhibitor for TBK1 and IKKε, demonstrating IC50 values of 13 nM and 59 nM, respectively. This compound exhibits significantly reduced activity, by 100- to 1000-fold, against other protein kinases, such as PDK1, PI3K family members, and mTOR[1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 6-8 weeks |
| Description | TBK1/IKKε-IN-4, a 6-aminopyrazolopyrimidine derivative, serves as a potent, selective inhibitor for TBK1 and IKKε, demonstrating IC50 values of 13 nM and 59 nM, respectively. This compound exhibits significantly reduced activity, by 100- to 1000-fold, against other protein kinases, such as PDK1, PI3K family members, and mTOR[1]. |
| Targets&IC50 | TBK1:13 nM (IC50), IKKε:59 nM (IC50) |
| In vitro | TBK1/IKKε-IN-4 (Compound II; 96 hours; A549 and HCC44 cells) demonstrates selective toxicity in TBK1-dependent cancer cell lines (IC50 of ~4.2 μM for H441 cells and IC50 of ~0.4 μM for A549 cells)[1]. TBK1/IKKε-IN-4 (Compound II; 0-2 μM; 30 minutes; HCC44 cells) inhibits AKT activity[1]. TBK1/IKKε-IN-4 (Compound II) inhibits LPS-induced expression of IFNβ (IC50 = 62 nM) and the IFNβ target genes IP10 (IC50 = 78 nM) and Mx1 (IC50 = 20 nM). It effectively blocks TLR3-dependent IRF3 nuclear translocation (IC50 < 100 nM) without impairing TNFR1-dependent p65 NFκB nuclear translocation at doses up to 20 μM[1]. |
| Synonyms | TBK1/IKKε-IN-4 |
| Molecular Weight | 533.62 |
| Formula | C28H35N7O4 |
| Cas No. | 1381930-17-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 70 mg/mL (131.18 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.18 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.